"With as much as $17 billion in sales in 2024 and over $10 billion in the first half of 2025, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S ( NYSE: NVO). This Scandinavian economic behemoth is one of the highest-valued companies in Europe at over $500 billion, which exceeds Denmark's entire gross domestic product."
"In addition to diabetes drugs, the company also makes drug treatments for wound healing, menopausal hormone replacement, and human growth hormone. Besides Ozempic and Wegovy, the company has made progress recently on other obesity drugs in its pipeline, including amycretin and CagriSema. Novo Nordisk has reported promising clinical trial results for a new weight-loss pill, a major corporate restructuring, and continued success for its blockbuster drugs."
Novo Nordisk's GLP-1 drugs, led by Ozempic and Wegovy, generated massive sales of about $17 billion in 2024 and over $10 billion in the first half of 2025. The company began as a Copenhagen insulin maker and evolved into a global pharmaceutical leader valued above $500 billion. Ozempic and Wegovy were developed for diabetes, with weight loss proving a profitable side effect. The company is advancing additional obesity programs such as amycretin and CagriSema and reported promising clinical trial results for an oral weight-loss pill. Corporate restructuring has accompanied blockbuster growth, and investors face uncertainty when projecting long-term stock performance.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]